Citi Investment Research has a Hold rating and a $17 price target on shares of Pfizer Inc. PFE.
In a note to clients, Citi writes, "We believe PFE's new CEO could announce a strategic review of its #5 ranked global nutritional business, similar to PFE's Oct. '10 announcement to review Capsugel (by 1Q11). We believe it makes strategic & financial sense to divest the Nutritional business, either through a tax-efficient spin/split-off structure similar to BMY's Mead Johnson (MJN) transaction rather than a sale. We could see a deal fetching $8B-$9B (4.0x-5.0x EV/sales or 13.0x-15.0x EV/EBITDA)."
Shares of PFE closed at $18.15 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsCiti Investment ResearchHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in